Updated HIV Treatment Recommendation on Use of Cabotegravir and Rilpivirine
To the Editor Long-acting injectable cabotegravir and rilpivirine (CAB-RPV) is approved for people with HIV who have viral suppression with oral antiretroviral therapy (ART), no known or suspected resistance to either drug, and no chronic hepatitis B. In clinical trials, switching to this injectable…